Top San Francisco Bay Area, CA Pharmaceutical Companies (54)
Self-Driven Neurological Assessments.
Triton Medical Robotics is on a mission to transform clinical practice and improve the lives of patients, caregivers, and society as a whole by creating highly innovative, category-defining robotics that give doctors incredible new capabilities to provide significantly better care. Triton, a division of Neptune Medical, is an innovative, venture capital funded medical device startup headquartered in Silicon Valley in Burlingame, CA. We have already commercialized novel medical devices using our technology. Now the team at Triton is building something truly unique: a fully flexible medical robot that enables doctors to reach deep into human anatomy. We think our robot will disrupt flexible endoscopy and set a new standard in outcomes for decades to come. Triton Medical Robotics combines cutting-edge technical innovation, product and process development expertise, deep clinical understanding, and continuous clinician input to deliver highly enabling medical robotic systems that address enormous unmet needs across multiple major medical indications. We work together with a shared sense of passion and urgency to understand the needs of our clinician partners and provide safe, reliable solutions that make it easy for them to provide the best care for their patients.
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact. Recruitment Fraud Alert Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit. We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Our pipeline includes two investigational oral SYK inhibitors, entospletinib and lanraplenib, which are being developed to treat acute myeloid leukemia (AML). Together the compounds have the potential to target mutations present in more than two-thirds of patients with AML. We are also advancing an oral CDK9 inhibitor, KB-0742, to treat patients with solid tumors addicted to oncogenic transcription factor activity. KB-0742 is the first investigational medicine from our internal discovery platform to enter the clinic. Beyond these three investigational compounds, we are progressing additional discovery programs, including one focused on the MYC TRN and another focused on the AR TRN. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
Spring Discovery is accelerating the discovery of therapies for aging. By targeting the biological processes of aging itself, we aim to uncover new therapies for the diseases of old age — from cardiovascular to neurodegenerative disease — and increase our healthy lifespans. We've built a machine learning platform to accelerate experimentation for discovering such therapies. We're hiring! https://www.springdisc.com/#careers
Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. We hire the most brilliant minds because inventing for life depends on our work. Here, you'll find rewarding opportunities, diverse experiences, and an unwavering commitment to ethics and integrity. You'll collaborate with talented colleagues who share your sense of purpose. Our company will empower you to innovate, explore, and develop your full potential in our possibility-rich environment. Our team is constantly evolving, so if you are among the intellectually curious, join us—and start making your impact today.
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.
Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the health of their skin. Those working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals use AI to discover lifesaving drugs. Imagine what the rest of our team of 134,000 people at 260 companies in more than 60 countries across the world is accomplishing. We redefine what it means to be a big company in today’s world. Social Media Community Guidelines: http://www.jnj.com/social-media-community-guidelines
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
At BioNex Solutions, we develop instrumentation and integrated systems that solve the most demanding applications in biopharmaceutical, biotech, and academic research. Our hardware and software philosophy is to design single-purpose, high performance modules, and integrate them to produce the desired functionality. Rather than push a single, generalized product that tries to meet the needs of every customer, we prefer to tailor our control software to each customers' needs to make operation as simple as possible. ISO 9001:2008 & ISO 13485:2003 Certified
We are Amino Health, the leading data-driven healthcare guidance platform that makes it easy for plan members to navigate their unique benefits to find proven, trustworthy care for their specific needs. Partnering with health plans, third-party administrators, benefits administrators and concierge care vendors, Amino connects members to high-value providers and facilities at three times the rate of the baseline population, driving cost savings, increased member satisfaction, and improved health outcomes
At Mendel.ai, our mission is to use our novel AI aided by clinical experts to streamline global oncology research by organizing real world data and automating clinical trials. We build software to solve problems at each stage of the clinical trial process, from feasibility to post-trial pharmacovigilance. We strive for excellency, to be authentic and original, and to make a difference by greeting our challenges head on. Please visit our website, mendel.ai, to learn more about our company, goals, and values. Website
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
.png){kind=logo}
The Tivic Health team is dedicated to developing advanced bioelectronic solutions that treat disease, increase wellness and improve lives. Our initial focus is delivering sinus pain relief. ClearUP is new alternative for temporary relief of sinus pain. www.tivichealth.com Currently, the most recommended treatment for those experiencing recurring sinus pain is daily flushing of the nose with salt water. We believe people should have access to relief without pills, sprays and flushes.
